期刊文献+

阿托伐他汀对急性心肌梗死患者血浆高敏C-反应蛋白的作用及其对心功能的保护 被引量:8

暂未订购
导出
摘要 目的:探讨阿托伐他汀对急性心肌梗死患者血浆高敏C-反应蛋白(hs-CRP)的作用其心功能保护的作用。方法:收集68例确诊为急性心肌梗死的患者,随机给患者顿服20mg阿托伐他汀组(32例)和80mg阿托伐他汀组(36例)。分别于入院时、入院后24h及入院后1周检测血浆高敏-C反应蛋白、肌钙蛋白-T和采用心脏彩超评价两组患者的心功能。结果:入院后及入院24h后两组患者间血浆肌钙蛋白-T、心功能无明显差别;入院24h后,80mg阿托伐他汀组高敏-C反应蛋白水平较20mg组下降(P<0.05);入院1周后,与20mg阿托伐他汀组比较,80mg组血浆高敏-C反应蛋白、肌钙蛋白-T水平下降(P<0.05)而心功能明显提高(P<0.05)。结论:急性心肌梗死早期给予80mg阿托伐他汀具有较好的心功能保护作用,可能是通过下调血浆Hs-CRP水平,从而改善炎症反应及减少心肌细胞坏死和凋亡。
作者 唐湘
出处 《中国当代医药》 2010年第31期44-45,共2页 China Modern Medicine
  • 相关文献

参考文献6

  • 1Wang QD,Sjoquist PO.Myocardial regeneration with stem cells:pharmecological possibilities for efficacy enhancement[J].Phannacol Res,2006,53(4):331-340.
  • 2Sezer MT,Katirci S,Demir M,et al.Short-term effect of simvastatin treatment on inflammatory parametem in peritoneal dialysis patients[J].Scand J Urol Nephrol,2007,41 (5):436-441.
  • 3Hurlimann D,Enseleit F,Ruschitzka F.Rheumatoid arthritis,inflammation,and atherosclerosis[l].Herz,2004,29(8):760-768.
  • 4Kleemann R,Verschuren L,de Booij BJ,et al.Evidence for antiinflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro[J].Blood,2004,103(11):4188-4194.
  • 5隋喜斌.不稳定型心绞痛应用国产阿托伐他汀强化治疗的临床观察[J].中国医药导报,2010,7(10):114-115. 被引量:4
  • 6李晓燕.阿托伐他汀治疗急性冠脉综合征的临床分析[J].中国现代医生,2010,48(3):44-44. 被引量:8

二级参考文献9

共引文献9

同被引文献59

  • 1冯庚.危重症社区现场急救系列讲座——急性心肌梗死的发病机制和病理生理改变[J].中国全科医学,2006,9(6):519-520. 被引量:5
  • 2顾申红,姚震.阿托伐他汀对急性心肌梗死患者血清C反应蛋白的影响[J].海南医学,2007,18(2):46-47. 被引量:2
  • 3肖华,陈志坚,廖玉华,黄恺,郭和平.急性心肌梗死患者炎性因子表达与室性心律失常的关系[J].山东医药,2007,47(4):19-20. 被引量:8
  • 4叶任高.内科学[M]5版.北京:人民卫生出版社,2001.258.
  • 5Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty ) study. Circulation, 2004, 110:674-678.
  • 6Kim JS,Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary pereutaneous coronary intervention in ST- segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv, 2010, 3:332-339.
  • 7American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, OGara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidehnes. J Am Coil Cardiol, 2013,61 :e78-140.
  • 8LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352: 1425-1435.
  • 9Cannon C, Braunwald E, McCabe C, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes ( PROVE IT-TIMI 22 ). New Engl J Med, 2004, 350 : 1495-1504.
  • 10Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001, 285: 1711-1718.

引证文献8

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部